Need For Blinded Payment In Randomized Trials Is Recognized In Recent Bills
This article was originally published in The Gray Sheet
Executive Summary
Recent legislation is recognizing the need to blind patients and providers to sources of reimbursement in clinical trials to ensure scientifically valid results
You may also be interested in...
Medicare Bill Becomes Law: Industry Focuses On What Didn’t Make the Cut
A Medicare bill made law last week was of interest to device firms as much or more for what it did not contain than for what it did include
CMS Maintains Status Quo On Clinical Trial Coverage, Again
Under intense pressure from Congress, industry and the medical research community, CMS has decided to maintain the status quo for coverage of routine costs in clinical trials
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.